154825-97-5

Basic information

• Product Name: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE
• Synonyms: methyl 2-(4-bromophenyl)-2-methylpropanoate;α,α-diMethyl-(4-broMophenyl)acetic acid Methyl ester;Benzeneacetic acid,4-broMo-a,a-diMethyl-, Methyl ester;Benzeneacetic acid, 4-bromo-α,α-dimethyl-, methyl ester;2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE;p-Bromo-alpha,alpha-Dimethylphenylacetic acid methyl ester;2-methyl-2-(p-bromophenyl)propionic acid methyl ester;P-Bromo-a,a-DimethylPhenylaceticAcidMethylEster
• CAS NO: 154825-97-5
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12372
• EINECS: 1308068-626-2
• Product Categories: Intermediates;Miscellaneous Reagents;Aromatics Compounds;Aromatics
• Mol File: 154825-97-5.mol

Chemical Properties

• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: Colourless oil
• Density: 1.337
• Vapor Pressure: 0.00209mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: Refrigerator
• Water Solubility: 43mg/L at 20℃
• CAS DataBase Reference: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(154825-97-5)
• EPA Substance Registry System: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(154825-97-5)

Safety Data

• Hazardous Substances Data: 154825-97-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE is used as a key intermediate in the synthesis of various organic compounds. Its unique structure and reactivity allow it to be a versatile building block for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE is used as a starting material for the development of new drugs. Its chemical properties make it suitable for the synthesis of various drug candidates, which can be further modified and optimized for specific therapeutic applications.
Used in Chemical Research:
METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE is also used in chemical research as a model compound to study various reaction mechanisms and to develop new synthetic methodologies. Its unique structure provides researchers with valuable insights into the reactivity of similar compounds and helps in the design of novel synthetic routes.
Used in Material Science:
In the field of material science, METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE can be used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with enhanced characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C11H13BrO2/c1-11(2,10(13)14-3)8-4-6-9(12)7-5-8/h4-7H,1-3H3

Upstream product

• 1634-04-4 tert-butyl methyl ether 
• 32454-35-6 2-(4-bromophenyl)-2-methylpropionic acid 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 23426-63-3 2-bromo-2-methylpropionic acid methyl ester 
• 589-87-7 1,4-bromoiodobenzene 
• 71-43-2 benzene 
• 67-56-1 methanol 
• 83636-46-8 methyl 2-(4-bromophenyl)propanoate 
• 74-88-4 methyl iodide 

Downstream Products

• 154825-94-2 4-<4-(Methanesulfonyloxy)-1-butynyl>-α,α-dimethylbenzeneacetic acid methyl ester 
• 154825-95-3 4-<4-<4-(Hydroxydiphenylmethyl)-1-piperidinyl>-1-butynyl>-α,α-dimethylbenzeneacetic acid methyl ester 
• 154477-55-1 methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate 
• 83799-24-0 fexofenadine 
• 154825-96-4 fexofenadine methyl ester 
• 897935-07-8 5-[1-(4-bromophenyl)-1-methylethyl]-1H-1,2,4-triazol-3-amine 
• 32454-37-8 2,2-dimethyl-2-(4-bromophenyl)ethanol 
• 890839-10-8 methyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate 
• 1341205-92-2 2-methyl-2-(4-bromophenyl)propanehydrazide 
• 1341205-94-4 4-amino-5-[2-(4-bromophenyl)propan-2-yl]-4H-[1,2,4]-triazole-3-thiol 
• 1341205-86-4 6-(4-fluorophenyl)-3-[2-(4-bromophenyl)propan-2-yl][1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 1341205-87-5 3-[2-(4-bromophenyl)propan-2-yl]-6-(2,3,4-trifluorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 1341205-88-6 3-[2-(4-bromophenyl)propan-2-yl]-6-(2-trifluoromethoxyphenyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 1341205-89-7 6-(3,5-bistrifluoromethylphenyl)-3-[2-(4-bromophenyl)propan-2-yl][1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

PDE 10a Inhibitors for the Treatment of Type II Diabetes

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.

A chemoselective Reformatsky-Negishi approach to α-haloaryl esters

A practical synthesis of α-haloaryl esters has been achieved via a chemoselective Negishi coupling of poly-halogenated aromatics and Reformatsky reagents in the presence of catalytic Pd(dba)2 and Xantphos. This chemistry tolerates a variety of aryl halides and was successfully applied to the synthesis of Ibuprofen. The α-haloaryl ester products, exemplified by ethyl 2-(4-bromo-2-chlorophenyl)acetate (3a), can be further functionalized via palladium or copper catalysis to afford an array of α-aryl esters.

One-pot esterification and amide formation via acid-catalyzed dehydration and ritter reactions

Esterification of carboxylic acid is achieved using acetonitrile as a water trap. Water liberated during esterification is consumed in cyanide hydrolysis, thereby driving the esterification to completion. Substrates having carboxylic acid and nitrile groups undergo intramolecular dehydration and rehydration to amido esters in the absence of acetonitrile. Cyano acids also undergo esterification and Ritter reaction in one pot when excess alcohol is used. For the first time, we have observed an interesting Ritter reaction of primary alcohols, leading to ester amide product in one pot. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.